BLT2 is a pro-tumorigenic mediator during cancer progression and a therapeutic target for anti-cancer drug development
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Cho, Nam-Kyu | - |
dc.contributor.author | Joo, Young-Chul | - |
dc.contributor.author | Wei, Jun Dong | - |
dc.contributor.author | Park, Jae In | - |
dc.contributor.author | Kim, Jae-Hong | - |
dc.date.accessioned | 2021-09-06T11:37:19Z | - |
dc.date.available | 2021-09-06T11:37:19Z | - |
dc.date.created | 2021-06-14 | - |
dc.date.issued | 2013 | - |
dc.identifier.issn | 2156-6976 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/106562 | - |
dc.description.abstract | Cancer is a leading cause of death worldwide and has been linked to inflammation. Leukotriene B-4 (LTB4) is synthesized from arachidonic acid via the 5-lipoxygenase pathway and is a potent chemoattractant for inflammatory cells. LTB4 was recently shown to be associated with the pathogenesis of inflammatory diseases, including cancer. Of the two known LTB4 receptors, BLT1 and BLT2, the biological roles of the low-affinity LTB4 receptor 2, BLT2, have only recently been elucidated. This review focuses on recent discoveries regarding BLT2 and its roles in cancer progression and the downstream signaling mechanisms of the BLT2-linked signaling cascade in cancer cells. We believe that these findings will facilitate the development of new cancer treatments. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | E-CENTURY PUBLISHING CORP | - |
dc.subject | LEUKOTRIENE B-4 RECEPTOR | - |
dc.subject | NF-KAPPA-B | - |
dc.subject | ANDROGEN RECEPTOR | - |
dc.subject | PANCREATIC-CANCER | - |
dc.subject | SIGNAL TRANSDUCER | - |
dc.subject | UP-REGULATION | - |
dc.subject | BLT2-LINKED PATHWAY | - |
dc.subject | BLADDER-CANCER | - |
dc.subject | CELL-SURVIVAL | - |
dc.subject | MAST-CELLS | - |
dc.title | BLT2 is a pro-tumorigenic mediator during cancer progression and a therapeutic target for anti-cancer drug development | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Jae-Hong | - |
dc.identifier.wosid | 000331069400002 | - |
dc.identifier.bibliographicCitation | AMERICAN JOURNAL OF CANCER RESEARCH, v.3, no.4, pp.347 - 355 | - |
dc.relation.isPartOf | AMERICAN JOURNAL OF CANCER RESEARCH | - |
dc.citation.title | AMERICAN JOURNAL OF CANCER RESEARCH | - |
dc.citation.volume | 3 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 347 | - |
dc.citation.endPage | 355 | - |
dc.type.rims | ART | - |
dc.type.docType | Review | - |
dc.description.journalClass | 1 | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | LEUKOTRIENE B-4 RECEPTOR | - |
dc.subject.keywordPlus | NF-KAPPA-B | - |
dc.subject.keywordPlus | ANDROGEN RECEPTOR | - |
dc.subject.keywordPlus | PANCREATIC-CANCER | - |
dc.subject.keywordPlus | SIGNAL TRANSDUCER | - |
dc.subject.keywordPlus | UP-REGULATION | - |
dc.subject.keywordPlus | BLT2-LINKED PATHWAY | - |
dc.subject.keywordPlus | BLADDER-CANCER | - |
dc.subject.keywordPlus | CELL-SURVIVAL | - |
dc.subject.keywordPlus | MAST-CELLS | - |
dc.subject.keywordAuthor | Leukotriene B-4 receptor 2 (BLT2) | - |
dc.subject.keywordAuthor | leukotriene B-4 | - |
dc.subject.keywordAuthor | NADPH oxidase | - |
dc.subject.keywordAuthor | reactive oxygen species | - |
dc.subject.keywordAuthor | nuclear factor-kB | - |
dc.subject.keywordAuthor | cancer progression | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.